Soliqua 100/33

sanofi-aventis U.S. LLC🇺🇸 United States

FDA Page

Effective Date: Mar 18, 2026
Approval ID: 4bba538b-cf7c-4310-ae8f-cb711ed21bcc
Products: 1 registered
Version: 18

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use SOLIQUA 100/33 safely and effectively See full prescribing information for SOLIQUA 100/33. SOLIQUA 100/33 (insulin glargine and lixisenatide) injection, for subcutaneous use Initial U.S. Approval: 2016

Quick Stats

Total Products1

Labelers3

Label Sections40

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.